The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Statin Use Tied to Lower Risk of Inflammatory Bowel Disease

Statin Use Tied to Lower Risk of Inflammatory Bowel Disease

July 4, 2016 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Statin use is associated with a lower risk of developing inflammatory bowel disease (IBD), especially Crohn’s disease in older patients, new research suggests.

You Might Also Like
  • Patients Don’t Realize Smoking Worsens Inflammatory Bowel Disease
  • Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease

“Prior studies have suggested that statins can decrease inflammation and may improve IBD in patients who already have the disease. To our knowledge, this is the first study to show that statin exposure in patients without IBD is associated with a decreased risk of developing Crohn’s disease and ulcerative colitis,” Dr. Ryan Ungaro of the Icahn School of Medicine at Mount Sinai in New York tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study team used a large U.S. claims database to examine putative effects of statins on the risk of new onset IBD. Their analysis, published online June 14 in The American Journal of Gastroenterology, included more than 9,000 adults with Crohn’s disease (CD) or ulcerative colitis (UC) and some 46,000 matched controls.

Any statin exposure was associated with a significantly decreased risk of IBD (odds ratio, 0.68), CD (OR, 0.64) and UC (OR, 0.70). The effect was similar when stratified by type of statin and intensity of treatment. The apparent protective effect was strongest against CD in older patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Statins continued to be associated with reduced risk of new IBD diagnosis after controlling for potential confounders including use of antibiotics, hormone replacement therapy, oral contraceptives and cardiovascular medications, as well as comorbidities.

The lack of a dose-response relationship “may suggest that lower doses of statins may be sufficient at decreasing inflammation,” the authors say.

Statin exposure is a “potential new environmental factor that modulates the risk of IBD,” Dr. Ungaro tells Reuters Health. “It will also be interesting for future studies to explore if this effect in IBD is mediated through immunomodulatory properties or impact of statins on the vascular system.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

He adds, “Consideration should be given to studying statins as a potential add-on therapy in mild IBD. If our results are confirmed in other studies, statins may have a role as a preventative treatment for patients at high risk for developing IBD; however, further studies are needed to determine this.”

Strengths of the current analysis include the large nationally representative sample size. Limitations include use of retrospective data and use of prescriptions as a surrogate marker for patients actually taking the medication and the fact that the database did not include reliable information on potential confounders that may influence IBD risk, such as smoking, diet, early life exposures or family history of IBD.

The study had no commercial funding and the authors have no relevant disclosures.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Crohn's disease, inflammatory bowel disease, Statin, ulcerative colitis

You Might Also Like:
  • Patients Don’t Realize Smoking Worsens Inflammatory Bowel Disease
  • Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease
  • Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)